With Diagnostic Royalties on the Horizon, Compugen s Broad Approach Bears Fruit | GenomeWeb

At a time when many bioinformatics firms are wrestling with the “tools or targets” question, Compugen is starting to reap the benefits of a carefully balanced mix of software sales, collaborative research, and target discovery. Following on the news of a Jan. 15 platform deal with Abbott Laboratories, Compugen last week announced its first significant royalty-bearing partnership. Diagnostic Products Corporation (DPC) has licensed two novel prostate-specific proteins from Compugen for use in diagnostic kits for the detection of prostate and other cancers.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In Science this week: metagenomic-based technique for determining protein structure, and more.

An academic laments the rise of narcissism in the sciences, the Guardian reports.

Outgoing FDA commissioner Robert Califf writes in an editorial that the agency can help boost innovation.

The Trump transition team has asked NIH Director Francis Collins to remain at his post, though it's unclear for how long that will be.